tiprankstipranks
CStone Pharmaceuticals (HK:2616)
:2616
Hong Kong Market
2616
CStone Pharmaceuticals
RESEARCH TOOLSreports
Want to see HK:2616 full AI Analyst Report?

CStone Pharmaceuticals (2616) Stock News & Sentiment

4 Followers
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
Premium
Company Announcements
CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement
13d ago
2616
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
Premium
Company Announcements
CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push
14d ago
2616
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
Premium
Company Announcements
CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
16d ago
2616
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
Premium
Company Announcements
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
21d ago
2616
CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
Premium
Company Announcements
CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
1M ago
2616
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
Premium
Company Announcements
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
1M ago
2616
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
Premium
Company Announcements
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
1M ago
2616
More HK:2616 News >

2616 News on the Web

CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007
TipRanks News
Bullish
CStone Pharmaceuticals to Raise About HK$1.05 Billion via Discounted Share Placement
TipRanks News
Neutral
Goldman Sachs Sticks to Its Buy Rating for CStone Pharmaceuticals (2616)
TipRanks News
Neutral
CStone’s 2025 Loss Widens as R&D Spend Climbs Ahead of Pralsetinib NRDL Boost
TipRanks News
Neutral
CStone Fast-Tracks Global Phase III Plan After Strong Early Data for Trispecific Cancer Antibody CS2009
TipRanks News
Bullish
CStone’s Sugemalimab Wins Top ESMO Backing for Stage III Lung Cancer
TipRanks News
Bullish
CStone to Showcase Three ADC Pipeline Programs at 2026 AACR Meeting
TipRanks News
Bullish
Guoyuan Securities (HK) Reaffirms Their Buy Rating on CStone Pharmaceuticals (2616)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
HK:2616
Sector Average
Media Buzz
This Week2 articles
Weekly Average1.25 articles
News Sentiment
This Week100%
Sector Average70%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is HK:2616’s Media Buzz Sentiment?
2 articles about HK:2616 were published this week. In an average week, 1.25 articles are published.
    What is HK:2616’s weekly average amount of articles?
    In an average week, 1.25 articles about HK:2616 are published.
      What is HK:2616’s News Sentiment?
      100% of articles about HK:2616 were positive this week, compared to its sector average of 70%.
        Healthcare Stocks that are Trending in the News
        TVTXTravere Therapeutics
        HVOOpen Orphan Plc
        PBMPsyence Biomedical
        QDELQuidelOrtho
        Showing the stocks with the most bullish news sentiment over the past week